ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Cardiac Amyloid Treatment Boosts AVR Outcomes. 11/21/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 21, 2025. This episode summarizes 5 key cardiology studies on topics like Transthyretin amyloidosis and Surgical aortic valve replacement. Key takeaway: Cardiac Amyloid Treatment Boosts AVR Outcomes..
Article Links:
Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma. (The New England journal of medicine)
Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies. (European heart journal)
Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. (European heart journal)
Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. (European heart journal)
Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/
Featured Articles
Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41124218
Summary: Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.
Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40824531
Summary: High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer’s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.
Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40669514
Summary: Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.
Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40599126
Summary: surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.
Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40452225
Summary: Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
Transcript
Today’s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.
Article number two. Lipoprotein(a) and risk of dementia: findings from three cohort studies. High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer’s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.
Article number three. Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.
Article number four. Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.
Article number five. Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
Thank you for listening. Don’t forget to subscribe.
Keywords
Transthyretin amyloidosis, Surgical aortic valve replacement, Prognosis, Vascular dementia, Belzutifan, Tricuspid regurgitation, Lipoprotein(a), Alzheimer’s disease, Pheochromocytoma, Dementia, Electrocardiography, Aortic regurgitation, Aortic valve replacement, Transcatheter aortic valve replacement, Artificial intelligence, Cardiac amyloidosis, Mitral regurgitation, Atherosclerotic cardiovascular disease, Antitumor activity, Environmental footprint, Valvular heart disease, Paraganglioma, HIF-2 alpha inhibitor, Aortic stenosis, Carbon emissions.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Cardiac Amyloid Treatment Boosts AVR Outcomes. 11/21/25 first appeared on Cardiology Today.
Article Links:
Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma. (The New England journal of medicine)
Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies. (European heart journal)
Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. (European heart journal)
Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. (European heart journal)
Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/cardiac-amyloid-treatment-boosts-avr-outcomes-11-21-25/
Featured Articles
Article 1: Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41124218
Summary: Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.
Article 2: Lipoprotein(a) and risk of dementia: findings from three cohort studies.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40824531
Summary: High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer’s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.
Article 3: Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40669514
Summary: Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.
Article 4: Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40599126
Summary: surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.
Article 5: Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40452225
Summary: Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
Transcript
Today’s date is November 21, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor. This medication targets dysregulation of the HIF-2 alpha pathway, which drives most cases of metastatic pheochromocytoma and paraganglioma. It offers antitumor activity for patients with advanced pheochromocytoma or paraganglioma. This phase two international single-group trial included 72 participants with locally advanced disease.
Article number two. Lipoprotein(a) and risk of dementia: findings from three cohort studies. High lipoprotein(a) is a recognized causal risk factor for atherosclerotic cardiovascular disease. This study investigated the association between lipoprotein(a) levels and the risk of Alzheimer’s disease or vascular-related dementia. It analyzed lipoprotein(a) measurements from 539478 individuals across three large cohort studies, including the Copenhagen General Population Study and the Copenhagen City Heart Study. The findings clarify the role of lipoprotein(a) in dementia, especially significant given that lipoprotein(a) lowering drugs are currently in clinical trials.
Article number three. Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study. Artificial intelligence-enhanced electrocardiography (AI-E. C. G.) models were developed to diagnose and predict future moderate or severe regurgitant valvular heart diseases. These regurgitant valvular heart diseases include mitral regurgitation, tricuspid regurgitation, and aortic regurgitation. The A. I. E. C. G. models were developed using a large dataset of 988618 electrocardiogram and transthoracic echocardiogram pairs. This development provides a tool to potentially improve outcomes through earlier intervention for significant valvular heart disease.
Article number four. Carbon emission analysis of aortic valve replacement: the environmental footprint of transcatheter vs. surgical procedures. A life cycle assessment calculated the carbon emissions associated with open surgical aortic valve replacement (S. A. V. R.) and transcatheter aortic valve replacement (TAVR). The analysis compared procedures performed in the operating room and the cardiac catheterization lab. The total carbon footprint was determined for 10 S. A. V. R. cases, 10 operating room TAVR cases, and 10 cardiac catheterization lab TAVR cases. This study provides a foundational understanding of the environmental footprint of these critical cardiovascular procedures.
Article number five. Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Concomitant aortic stenosis and transthyretin-associated cardiac amyloidosis is an increasingly recognized cause of structural heart failure. Aortic valve replacement improves prognosis in this patient population. This study investigated the prognostic implications of transthyretin-associated cardiac amyloidosis-specific medication in patients with both aortic stenosis and cardiac amyloidosis. It found that transthyretin-associated cardiac amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
Thank you for listening. Don’t forget to subscribe.
Keywords
Transthyretin amyloidosis, Surgical aortic valve replacement, Prognosis, Vascular dementia, Belzutifan, Tricuspid regurgitation, Lipoprotein(a), Alzheimer’s disease, Pheochromocytoma, Dementia, Electrocardiography, Aortic regurgitation, Aortic valve replacement, Transcatheter aortic valve replacement, Artificial intelligence, Cardiac amyloidosis, Mitral regurgitation, Atherosclerotic cardiovascular disease, Antitumor activity, Environmental footprint, Valvular heart disease, Paraganglioma, HIF-2 alpha inhibitor, Aortic stenosis, Carbon emissions.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Cardiac Amyloid Treatment Boosts AVR Outcomes. 11/21/25 first appeared on Cardiology Today.
In God we trust